Clinical predictive factors of pathologic complete response in locally advanced rectal cancer by DE FELICE, Francesca et al.
Oncotarget33374www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 22
Clinical predictive factors of pathologic complete response in 
locally advanced rectal cancer
Francesca De Felice1, Luciano Izzo2, Daniela Musio1, Anna Lisa Magnante1, 
Nadia Bulzonetti1, Federico Pugliese2, Paolo Izzo2, Pierfrancesco Di Cello2, 
Pietro Lucchetti2, Sara Izzo2, Vincenzo Tombolini1,3
1 Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy
2 Department of Surgery “Pietro Valdoni”, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy
3Spencer-Lorillard Foundation, Rome, Italy
Correspondence to: Francesca De Felice, email: fradefelice@hotmail.it
Keywords: rectal cancer, concomitant treatment, radiotherapy, neoadjuvant, athologic complete response
Received: January 30, 2016    Accepted: March 02, 2016    Published: March 16, 2016
ABSTRACT
Background: Predictive factors of pathologic complete response (pCR) after 
neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) 
are still not identified. The purpose of this study was to define them.
Materials and Methods: Data from consecutive LARC patients treated between 
January 2008 and June 2014 at our Institution were included in the analysis. All 
patients were treated with a long course of nCRT. Demographics, initial diagnosis 
and tumor extension details, as well as treatment modalities characteristics were 
included in the univariate and logistic regression analysis.
Results: In total 99 patients received nCRT, of whom 23 patients (23.2%) 
achieved pCR. Patients with and without pCR were similar in term of age, sex, 
comobidities, BMI and tumor characteristics. Multivariate logistic regression indicated 
that pre-treatment tumor size ≤ 5 cm was a significant predictor for pCR (p = 0.035), 
whereas clinical N stage only showed a positive trend (p = 0.084).
Conclusions: Tumor size at diagnosis could be used to predict pCR, and thus to 
individualize therapy in LARC patients management. Validation in other studies is needed.
INTRODUCTION
Neoadjuvant chemoradiotherapy (nCRT) is the 
standard treatment in locally advanced rectal cancer 
(LARC), due to the proven benefit in term of local 
recurrence and sphincter preservation [1–2]. Based on 
the observation that a greater tumor regression to nCRT 
resulted in superior survival, nowadays pathologic 
complete response (pCR) rate is becoming a focus of 
interest [3]. A recent meta-analysis has suggested that 
patients with pCR after nCRT had significantly better 
long-term clinical outcomes than did those with no-pCR, 
with 5-years rate of overall survival, disease free survival 
and risk for local recurrence of 87.6%, 83.3% and 2.8%, 
respectively [4]. It is important to note that there is no 
consensus of independent predictive factors for achieving 
pCR. Evidence of predictive value should be considered 
in order to optimize and individualize treatment approach. 
Nowadays it is assumed that all LARC are a homogenous 
group and validation of predictive factors could be useful 
to stratify patients to receive investigational approaches 
[5–6].
The purpose of the study was to identify the main 
predictive factors of pCR after nCRT in LARC that could 
be used in the next future for treatment decision making.
MATERIALS AND METHODS
Patient selection
Medical records of consecutive patients with 
LARC treated with nCRT between January 2008 and 
June 2014 were retrospectively reviewed. The study 
was approved by the Institutional Gastro-Intestinal 
Tumor Board at the Policlinico Umberto I, “Sapienza” 
University of Rome. All patients signed an informed 
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consent. Patients were clinically staged on digito-rectal 
examination, endorectal ultrasound, chest, abdomen 
and pelvis computed tomography (CT) and/or pelvic 
magnetic resonance imaging (MRI) as T3-4 and/or with 
positive regional lymph- node, without any evidence of 
distant metastases. All patients had biopsy-proven rectal 
adenocarcinoma. Exclusion criteria included synchronous 
tumors, cardiovascular disease, history of neurological or 
psychiatric disorders, or previous pelvic radiotherapy.
Treatment
All patients were treated with a long course 
of nCRT. Radiotherapy (RT) was delivered with a 
3D-conformational multiple field technique at a dose of 
45 Gy (1,8 Gy/fraction) to the whole pelvis plus a 5,4–9 
Gy (1,8 Gy/fraction) to the tumor volume. Chemotherapy 
(CHT) consisted of weekly OXP (50 mg/m2 , day 1) and 
five daily continuous infusions of 5-FU (200 mg/m2/
day) of each week of RT, based on promising results in 
high rate of pCR [7–8]. Surgery was planned 7–9 weeks 
after the end of nCRT and its type was left to surgeon’s 
discretion.
Data collection
Data collected included: demographics (sex, age, 
PS, BMI, comorbidities), initial diagnosis and tumor 
extension (T dimension, TNM classification, grading, 
tumor distance from anal verge), treatment modalities 
(both total and daily doses of RT, number cycles of 
concomitant CHT, interruption CHT, time interval 
between nCRT and surgery).
The presence of diabetes, pulmonary or hepatic 
disease was considered as comorbidity.
T dimension was evaluated on endoscopic examination. 
It was expressed in centimeters (cm) and a cut-off of 
5 cm was used. The rationale behind using 5 cm as a cut-
off for dimension was that this value is used as a cut-off 
for several dimensional cancer TNM evaluation, and has 
been demonstrated to be of prognostic value [9–10]. TNM 
classification was evaluated on CT and/or MRI exams.
pCR was defined as the absence of any residual tumor 
cells detected in the operative specimen, both at the primary 
tumor site and regional lymph nodes (ypT0N0Mx).
Statistical analysis
Standard descriptive statistics were used to evaluate 
the distribution of each factor. Continuous variables were 
reported as means (range) and categorical variables as 
frequencies or percentages. The association between 
categorical variables was evaluated for significance by 
chi-square test. Quantitative variables were compared 
using the Mann–Whitney rank test. Variables with a 
p-value ≤ 0.25 on univariate analysis were included in the 
logistic regression analysis. In the multivariate regression 
model, continuous variables were dichotomized. Statistical 
analyses were performed using RStudio-0.98.1091 
software. All reported p values were two-sided, and 
p-values lower than 0.05 were considered significant.
RESULTS
Patient characteristics
Overall 99 patients were reviewed and included in 
the study. Patient baseline characteristics were presented 
in Table 1. Median age was 63.8 years (range 38 - 79) 
and 66 patients (66.7%) were male. The vast majority of 
patients had positive lymph nodes at diagnosis (n = 80; 
80.8%). All patients received same RT total dose, as well 
as CHT regimen. In total 23 patients (23.2%) achieved 
pCR while 76 (76.8%) had no-pCR. There were no 
significant differences between pCR and no-pCR groups 
in term of age, sex, comobidities, BMI, as well as tumor 
characteristic including disease stage, tumor size and 
distance from anal verge.
Univariate analysis
On univariate analysis, number of cycles of 
concomitant CHT ( > 4 vs ≤ 4) and suspension CHT (yes 
vs no) were found to be near significant (p = 0.21 and 0.1 
respectively). The time interval between nCRT and surgery 
was also investigated. It was analyzed as ≤ 8 weeks vs > 
8 weeks and there was no significant difference in pCR 
detection (p = 0.25).
Multivariate logistic regression analysis
Logistic regression showed that pre-treatment 
tumor dimension < 5 cm (p = 0.035) was a significant 
predictor for pCR, whereas clinical N0-1 stage only 
indicated a positive trend (p = 0.084). The other variables 
that were evaluated (tumor distance from anal verge, 
number cycles of concomitant CHT, suspension CHT 
and time interval between nCRT and surgery) were not 
significantly associated with pCR. Details are shown in 
Table 2.
DISCUSSION AND CONCLUSIONS
Our results showed that pCR to nCRT in primary 
lesion in the setting of LARC was achieved in 23.2% of 
patients. Multivariate data analysis supported that patients 
with a tumor diameter ≤ 5 cm were more likely to achieve 
pCR after nCRT (OR 0.25; p-value 0.035), whereas it only 
demonstrated a positive trend between N stage and pCR. 
Furthermore no correlation between pCR rate and surgical 
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time interval was found. A small number of concomitant 
CHT cycles and interrution of CHT during RT treatment 
were only near associated with pCR in the univariate 
analysis.
We may ask why these results are interesting.
Over the past decade there has been a substantial 
progress in LARC management, thanks to optimization of 
both surgical and RT techniques. Independently of tumor 
Table 1: Baseline characteristics of patients population
Characteristics Patient (%) p-value
Total pCR no-pCR
Sex 0.67
 Male 66 (66.7) 14 (60.9) 52 (68.4)
 Female 33 (33.3) 9 (39.1) 24 (31.6)
Age 0.66
 ≤ 70 76 (76.8) 19 (82.6) 57 (75)
 > 70 23 (23.2) 4 (17.4) 19 (25)
BMI 0.67
 ≤ 35 kg/m2 97 (98) 23 (100) 74 (97.4)
 > 35 kg/m2 2 (2) 0 (0) 2 (2.6)
Comorbidities 0.98
 No 51 (51.5) 13 (56.5) 38 (50)
 Yes 48 (48.5) 10 (43.5) 38 (50)
T classification 0.86
 2 2 (2) 1 (4.3) 1 (1.3)
 3 85 (85.9) 19 (82.6) 66 (86.8)
 4 12 (12.1) 3 (13.1) 9 (11.9)
N classification 0.21
 0 19 (19.2) 5 (21.7) 14 (18.4)
 1 39 (39.4) 6 (26.1) 33 (43.4)
 2 41 (41.4) 12 (52.2) 29 (38.2)
Overall stage 0.22
 II 19 (19.2) 5 (21.7) 14 (18.4)
 IIIA 1 (1) 0 (0) 1 (1.3)
 IIIB 42 (42.4) 7 (30.4) 35 (46.1)
 IIIC 37 (37.4) 11 (47.9) 26 (34.2)
Tumor dimension 0.22
 ≤ 5 cm 65 (65.7) 18 (78.3) 47 (61.8)
 > 5 cm 34 (34.3) 5 (21.7) 29 (38.2)
Distance from anal verge 0.28
 ≤ 5 cm 56 (59.6) 14 (60.9) 42 (55.3)
 > 5 ≤ 8 cm 22 (22.2) 2 (8.7) 20 (26.3)
 > 8 cm 21 (21.2) 7 (30.4) 14 (18.4)
pCR: pathologic complete response; BMI: body mass index; T: tumor; N: node
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response to neo-adjuvant treatment, the current paradigm 
is to treat all LARC with trimodality therapy, including 
RT, CHT and surgery [1].
Recent data support that pCR following nCRT is 
associated with excellent long-term survival, with low 
rates of local recurrence and distant failure [11]. This 
issue has achieved relevance to guide decision-making, 
because pCR has begun to be considered as surrogate of 
more conservative treatment approach, including a “wait 
and see” policy, in selected cases [1, 8].
The median pCR rate is 16.5% (range 13% - 22.2%) 
in the main randomized phase III trials of LARC treated 
with nCRT [12–15]. Our pCR incidence is at the higher 
end of the range. It should be probably related to the high 
responsiveness to nCRT scheme used, with the addition 
of weekly oxaliplatin to the standard fluorouracil nCRT 
regime. Indirectly it should be also associated with a dose-
level relationship between concomitant CHT and pCR, 
leading to the detention of near significant predictive value 
of CHT parameters in the univariate analysis. However 
the robustness of this hypothesis needs to be confirmed, 
considering that only the German CAO/ARO/AIO-04 trial 
reported a higher pCR rates when oxaliplatin was added to 
standard nCRT (17% vs 13%; p = 0.038) [12].
Currently there is no evidence on which clinical 
parameter confers a pCR advantage after nCRT. Several 
studies have attempted to identify potential predictive 
factors associated with pCR [16–20]. Details are shown in 
Table 3. Smaller tumor size was the most common factor 
related to an increased rate of pCR.
Our results were consistent with these data of the 
recent medical literature. Garland et al [16] evaluated 
factors of pCR in 297 patients receiving nCRT and clinical 
tumor size was found to be independent predictor for pCR 
(p = 0.036). Tumor size was assessed by endoscopist at 
the time of pre-treatment colonoscopy and was scaled 
in discrete intervals of < 3.5 cm, 3.5-7 cm and > 7 cm. 
Statement on tumor size scale selection was not reported. 
The majority of patients (58.4%) had lesion of 3.5-7 cm.
Pre-nCRT size (p = 0.001) was identified to be 
univariate predictor for pCR in Park et al cohort of 249 
patients [19]. Pre-nCRT tumor size was assessed using 
digito-rectal examination and any available colonoscopic 
or radiologic imaging results. The cut-off point of size 
stratification was set at 4 cm (≤ 4 cm vs > 4 cm), but its 
selection criterion was not specified. Nevertheless the 
true effect-size significance could be questionable, due to 
the different scale used to stratified pretreatment lesion.
Although we looked at different cut-off, results remained 
comparable: greater tumor diameter predicts lower pCR.
Clinical nodal status at diagnosis was incorporated 
in the multivariate analysis. The OR for pretreatment 
nodal stage > N1 was 2,65 (95% CI 0.97 – 12.62). Thus 
patients with N2 category of disease were about 1.5 time 
less likely to achieve pCR after nCRT than those with 
metastasis in 1-3 regional lymph nodes. Because of the 
wide confidence interval for this finding, conclusions 
about the effect of nodal involvement at diagnosis was 
difficult to make. Maybe the trend was not statistically 
significant probably because of small sample size. 
Otherwise if we compare our results with those of other 
series that evaluated the prognostic impact of nodal status 
in pCR, data seem to strongly suggest that nodal status 
affect pCR rate. In their retrospective analysis, Garland et 
al. reported an OR for pretreatment clinical nodal status of 
4.38 (95% CI 1.01-19.02), which is similar to our findings 
Table 2: Logistic regression analysis:predictors of pathologic complete response (pCR)
Variable OR 95% CI p-value
Interruption CHT 0.145
 yes (no) 3.41 0.45 - 16.66
Interval between nCRT and S 0.178
 > 8 w (≤ 8 w) 2.13 0.56 - 5.61
T dimension 0.035
 > 5 cm (≤ 5 cm) 0.25 0.1 - 3.44
Nodal status 0.084
 N2 (N0-1) 2.65 0.97 - 12.62
Cycles CHT 0.755
 ≤ 4 (> 4) 0.71 0.13 - 15.04
Distance from anal verge 0.494
 > 8 (≤ 8 cm) 1.57 0.5 - 25.83
OR: odds ratio; CI: confidence interval; CHT: chemotherapy; nCRT: neoadjuvant chemoradiotherapy; S: surgery; w: weeks; 
T: tumor; N: nodes
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[16]. Surely the role of imaging modalities to assess lymph 
nodes involvement is prone to bias. Accurate N stage is 
essential to select patients and predicting clinical N status 
remains an unresolved problem. A meta-analysis revealed 
a slightly but not significantly superiority of endoluminal 
ultrasound over CT and MRI in diagnosing involved nodes 
[21]. The poor accuracy for lymph nodes assessment at 
MRI was recently confirmed by Al-Sukhni et al [22]. They 
performed a systematic review and meta-analysis of 21 
studies. Results showed that MRI had 77% sensitivity and 
71% specificity for N involvement. However, considering 
that this setting of patients received nCRT, it is difficult to 
evaluate a posteriori whether differences in clinical and 
pathological nodal stage can be attributed to the nCRT 
alone. Importantly nodal status appears to be predictor of 
pCR.
In our cohort time interval between nCRT and 
surgery was not correlated with pCR both on univariate 
and logistic regression analysis. This is an important result 
within literature data. Extending the interval between 
nCRT and surgery did not significantly increase the 
proportion of patients achieving pCR [23–25]. By contrast 
a recent systematic review showed a probably benefit in 
prolonging the time interval but a statistical analysis was 
not performed due to many differences between studies 
included, with a large degree of variation in interval length 
[26]. One meta-analysis showed that patients operated 
after 6-8 weeks had an estimated increase in the relative 
risk of pCR by 42%, but it was a retrospective data meta-
analysis and thus results should be taken with caution [27]. 
Indeed there are no solid data to confirm the real effect 
of delaying surgery on clinical practice and discrepancy 
may be explained by arbitrary selection of nCRT-surgery 
intervals. Further prospective randomized trials are the 
only way to answer the question of time interval and its 
correlationon oncologic outcomes.
This study was limited because it was a single-
institute study with a small sample size. Serum CEA 
level was not considered in our analysis, because this 
parameter is susceptible to inter-laboratory variations and 
not routinely recorded at our Department. On the other 
hand homogeneity in patients population data, as well 
as in treatment approach represent the principal analysis 
force. Results should be interpreted cautiously due to the 
retrospective study nature. That tumor size represents 
a robust predictive pCR factor remains to be shown 
definitively. Anyway a combination of retrospective 
literature data may be required to have the most clinical 
utility in LARC management.
This study demonstrated an association between 
tumor diameter ≤ 5 cm and pCR in LARC patients treated 
with nCRT. Time interval between the end of nCRT 
and surgery was not associated with pCR. Randomized 
trials are need. Waiting for those data, our results should 
contribute to develop individualized treatment approach.
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